QOP
HRTX icon

Quinn Opportunity Partners’s Heron Therapeutics HRTX Stock Holding History

Quinn Opportunity Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Hold
175,344
– – 0.01% 337
2025
Q4 		$228K Hold
175,344
– – 0.01% 325
2025
Q3 		$221K Hold
175,344
– – 0.02% 278
2025
Q2 		$363K Sell
175,344
-104,656
-37% -$214K 0.03% 264
2025
Q1 		$616K Sell
280,000
-100,000
-26% -$194K 0.04% 254
2024
Q4 		$581K Buy
+380,000
New +$616K 0.04% 250
2024
Q2 		– Sell
-72,097
Closed -$200K – 299
2024
Q1 		$200K Hold
72,097
– – 0.02% 214
2023
Q4 		$123K Hold
72,097
– – 0.01% 213
2023
Q3 		$74.3K Hold
72,097
– – 0.01% 218
2023
Q2 		$83.6K Sell
72,097
-20,000
-22% -$35.7K 0.01% 195
2023
Q1 		$139K Buy
+92,097
New +$231K 0.01% 212

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Quinn Opportunity Partners's HRTX Position: Q1 2026 in Review

Quinn Opportunity Partners held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 175,344 shares worth $140K. The position accounts for 0.01% of the portfolio, ranked #337.

Quinn Opportunity Partners first reported a position in HRTX in Q1 2023 and has held it in 11 quarters since. The position peaked at $616K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Quinn Opportunity Partners held 175,344 shares of Heron Therapeutics worth $140K as of Q1 2026.
  • Quinn Opportunity Partners left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.01% of Quinn Opportunity Partners's portfolio in Q1 2026, its #337 holding.
  • Quinn Opportunity Partners first reported a position in Heron Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Quinn Opportunity Partners's Heron Therapeutics position peaked at $616K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.